Free Trial

Cogent Biosciences (COGT) Stock Price, News & Analysis

Cogent Biosciences logo
$12.49 +0.29 (+2.38%)
Closing price 04:00 PM Eastern
Extended Trading
$12.48 -0.01 (-0.08%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cogent Biosciences Stock (NASDAQ:COGT)

Key Stats

Today's Range
$12.31
$12.95
50-Day Range
$4.77
$12.49
52-Week Range
$3.72
$12.94
Volume
3.68 million shs
Average Volume
1.63 million shs
Market Capitalization
$1.42 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.70
Consensus Rating
Moderate Buy

Company Overview

Cogent Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
71st Percentile Overall Score

COGT MarketRank™: 

Cogent Biosciences scored higher than 71% of companies evaluated by MarketBeat, and ranked 308th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cogent Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 7 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Cogent Biosciences has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Cogent Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Cogent Biosciences are expected to grow in the coming year, from ($2.42) to ($2.20) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cogent Biosciences is -6.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cogent Biosciences is -6.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cogent Biosciences has a P/B Ratio of 9.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Cogent Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    11.75% of the float of Cogent Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Cogent Biosciences has a short interest ratio ("days to cover") of 4.9.
  • Change versus previous month

    Short interest in Cogent Biosciences has recently decreased by 24.94%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Cogent Biosciences does not currently pay a dividend.

  • Dividend Growth

    Cogent Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.75% of the float of Cogent Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Cogent Biosciences has a short interest ratio ("days to cover") of 4.9.
  • Change versus previous month

    Short interest in Cogent Biosciences has recently decreased by 24.94%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Cogent Biosciences has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 20 news articles for Cogent Biosciences this week, compared to 4 articles on an average week.
  • Search Interest

    7 people have searched for COGT on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Cogent Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cogent Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $24,999,993.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 7.29% of the stock of Cogent Biosciences is held by insiders.

  • Read more about Cogent Biosciences' insider trading history.
Receive COGT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cogent Biosciences and its competitors with MarketBeat's FREE daily newsletter.

COGT Stock News Headlines

Leerink Partnrs Issues Pessimistic Outlook for COGT Earnings
The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
FY2027 Earnings Forecast for COGT Issued By Leerink Partnrs
See More Headlines

COGT Stock Analysis - Frequently Asked Questions

Cogent Biosciences' stock was trading at $7.80 on January 1st, 2025. Since then, COGT stock has increased by 60.1% and is now trading at $12.49.

Cogent Biosciences, Inc. (NASDAQ:COGT) announced its quarterly earnings data on Tuesday, May, 6th. The technology company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.04.

Top institutional shareholders of Cogent Biosciences include Assenagon Asset Management S.A. (0.17%).
View institutional ownership trends
.

Shares of COGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cogent Biosciences investors own include Visa (V), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX), NVIDIA (NVDA) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
5/06/2025
Today
7/18/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:COGT
CIK
1622229
Fax
N/A
Employees
80
Year Founded
N/A

Price Target and Rating

High Price Target
$29.00
Low Price Target
$9.00
Potential Upside/Downside
+49.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82
Research Coverage
11 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.84)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$255.86 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-149.79%
Return on Assets
-75.61%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.13
Quick Ratio
5.13

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.32 per share
Price / Book
9.46

Miscellaneous

Outstanding Shares
113,860,000
Free Float
105,556,000
Market Cap
$1.42 billion
Optionable
Optionable
Beta
1.88
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:COGT) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners